Evidence map›Paper›PMID 36285323›Full record

ArticleChina CDC weekly2022

Emergence of a SARS-CoV-2 Omicron Subvariant BA.2.2 with a 454-Nucleotide Genomic Deletion - Sichuan Province, China, May 10, 2022.

Yuliang Feng, Xiang Zhao, Tao Luo, Zhixiao Chen, Huiping Yang, Na Chen, Xiaozhen Ma, Mingyuan Li, Weihua Zhang, Sikai Jia and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuliang FengSichuan Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Xiang ZhaoNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Tao LuoWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu City, Sichuan Province, China.
Zhixiao ChenNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Huiping YangSichuan Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Na ChenSichuan Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Xiaozhen MaSichuan Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Mingyuan LiWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu City, Sichuan Province, China.
Weihua ZhangCollege of Computer Science, Sichuan University, Chengdu City, Sichuan Province, China.
Sikai JiaWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu City, Sichuan Province, China.
Xun YuanGuang'an Center for Disease Control and Prevention, Guang'an City, Sichuan Province, China.
Ming PanSichuan Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Linlin ZhouWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu City, Sichuan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

OmicronSARS-Cov-2

Identifiers

PMID36285323
PMCPMC9579981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.